GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...

GSK said a dose of its RSV vaccine protected against illness over three years, according to new data presented at the CHEST ...

The UK High Court has ruled that two GSK respiratory syncytial virus (RSV) vaccine patents are invalid in an action involving ...

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and ...

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

Tata Motors' British luxury car unit, Jaguar Land Rover (JLR), reported a three percent decline in retail sales to 1,03,108 ...

GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...

GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a ...

GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three ...

Arexvy is the world's first approved RSV vaccine and results showed that after a single dose, cumulative efficacy over three full RSV seasons was clinically meaningful.

GSK said data from a late-phase study showed that its respiratory syncytial virus vaccine, Arexvy, granted protection over three full RSV seasons.

GSK's Arexvy RSV vaccine demonstrated 43.3% effectiveness in preventing severe illness in its third trial season, following 94.1% effectiveness initially and 64.2% in the second year. The vaccine, one ...